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Glossary
AGOG

American Gollege of Gbstetricians and Gynecologists.

ADA

American Diabetes Association.

ADIPS

Australasian Diabetes in Pregnancy Society.

GDM

Gestational diabetes mellitus.

GTT

Glucose tolerance test.

gtto

The fasting glucose result before a GTT.

gtt2

The 2 hour glucose result of a GTT.

IDDM

Insulin dependent diabetes mellitus.

LGA

Large for gestational age.

MGTT

A GTT where only the gtt2 is measured.

NDDG

National Diabetes Data Group.

NIDDM

Non insulin dependent diabetes mellitus.

PIH

Pregnancy induced hypertension.

RAGOG

Royal Australasian College of Obstetricians and
Gynaecologists.

SGN

Special care nursery.

SGA

Small for gestational age.

WHO

World Health Organisation.

INTRODUCTION
Disorders of carbohydrate tolerance have an immediate and significant impact
on the outcome of pregnancy. Pregnancy in women with established
diabetes, either insulin dependent diabetes mellitus (IDDM) or non insulin
dependent diabetes mellitus (NIDDM), has frequently been associated with an
adverse fetal outcome. The most frequently encountered adverse outcomes
are related to diabetic control in the first and the third trimesters. The
incidence of congenital malformations and early spontaneous abortions is
associated with poor maternal diabetic control at the time of conception and
during the first trimester. The incidence of macrosomia is largely determined
by maternal diabetic control during the last trimester. However it was noted
around fifty years ago that some women who had macrosomic infants
developed diabetes shortly after delivery or during a subsequent pregnancy.
Thus the concept of a disorder of carbohydrate metabolism or a degree of
carbohydrate intolerance intermediate between "normality" and established
diabetes came about.

This intermediate state is now known as gestational diabetes mellitus (GDM)
which is currently defined as "carbohydrate intolerance of variable severity
with onset or first recognition during pregnancy" (Metzger, 1991). A diagnosis
of GDM identifies a maternal/fetal unit at increased risk of certain
complications. For the fetus there are the immediate risks associated with the
availability of excessive nutrition during the last trimester. There is now an
increasing body of evidence that this abnormal intrauterine nutritional milieu
can result in problems in childhood, adolescence and in subsequent
generations. There is also the long term risk to the mother of developing
NIDDM in future years.

Despite knowledge about the risks associated with a diagnosis of GDM there
remains considerable controversy about whether the diagnosis actually exists
and, if it does exist, how it should be diagnosed and who should be tested.
The Australasian Diabetes in Pregnancy Society (ADIPS) and the American
Diabetes Association (ADA) recommend that all women should be tested in all
pregnancies. The American College of Obstetricians and Gynecologists
(AGOG) recommend that only women with certain risk factors should be tested
while the Royal Australian College of Obstetricians and Gynaecologists
(RACOG) have no policy about who should be screened but a
recommendation about the preferred method of screening!

Hunter et al (1989) in a chapter of a widely read and influential textbook of
obstetrics felt that, except for research purposes, all forms of glucose tolerance
testing in pregnancy should be stopped as the potential benefits did not
compensate for the actual disadvantages. One of the major concerns
expressed was related to the distress of being labelled "diabetic". A less
extreme and more reasonably argued approach against GDM as an entity
has been advanced by Jarrett (1993) who felt that any unfavourable obstetric
outcomes were more likely to have come about on the basis of maternal age
and weight rather than any disorder of maternal glucose metabolism. Ales et
al (1989) felt that the problem of macrosomia had been overated and
problems only developed if the fetus weighed more than 4500 g.

The proponents of GDM as a medical disorder worthy of immediate and long
term care have several serious conceptual and methodological problems to
overcome. There is no national or international consensus about the preferred
method of testing for glucose intolerance, the dose of glucose to be used and
whether the glucose tolerance test (GTT) alone is sufficiently accurate or

reproducible to be the sole diagnostic test. One test is being used to identify
different groups of risks in two different people. The GTT criteria currently used
for the diagnosis of GDM have been based on either the probability of the
mother converting to NIDDM (0"Sullivan et al, 1964) or derived by consensus
from non-pregnant criteria (WHO, 1980). No criteria for determining the
immediate and long term risks to the fetus have so far been validated.

There has in recent years been an increasing body of evidence from animal
experiments and both retrospective and prospective epidemiological data in
humans to suggest that many "adult" diseases have some of their origins in
disorders of fetal intrauterine nutrition. In addition, minor degrees of glucose
intolerance below the diagnostic criteria for GDM have been found to be
associated with many of the fetal complications found with unequivocal GDM.
These findings have led to the suggestion that there may well exist a
continuum of risk for the fetus associated with increasing levels of maternal
glucose below the diagnostic level for GDM.

The aim of this study is to examine certain aspects of fetal and maternal
outcomes in pregnancies not complicated by GDM and to relate these to the
maternal glucose levels. The hypothesis is that there will be a gradation of risk
associated with increasing maternal glucose levels.

LITERATURE REVIEW
Literature review - Historical considerations.
It is difficult to pinpoint exactly when it became apparent that some women
developed a reversible form of carbohydrate intolerance during pregnancy
and that this was associated with an increased fetal death rate and therefore
was a substantive clinical problem. As could be reasonably expected the
initial studies exploring the relationship between temporary maternal glucose
intolerance in pregnancy and an increased rate of fetal morbidity and mortality
were both retrospective and inferential.

The concept of a particular kind of diabetes associated with pregnancy and
antedating the onset of permanent diabetes in the mother by many years was
first given scientific credence by Miller et al in 1944. In a retrospective study
they found that the fetal mortality rate in pregnancies where diabetes
developed was five times higher than in a non-diabetic control group. Onethird of the mothers who developed diabetes during the pregnancy did not
require insulin and their fetal mortality was three times the background rate.
This group of women could be considered to have what is now known as GDM
though the possibility that they had NIDDM discovered during the pregnancy
was not explored. That these women had GDM could be inferred from the
observation that an increased perinatal mortality rate could be demonstrated
in pregnancies 15 to 20 years before the onset of clinically recognised
diabetes. In addition, the perinatal mortality rate increased the closer the
women came to the eventual diagnosis of diabetes.

Islet cell hypertrophy is a feature of stillborn fetuses of mothers with
established diabetes. In 1952 it was demonstrated that islet cell hypertrophy

could be found in stillborn infants of mothers without diabetes who
subsequently developed NIDDM (Van Beek, 1952). In 1958 Jackson et al
reported that the overall stillbirth rate in prediabetic women was 14% rising to
29% during the 5 years before the diagnosis of diabetes.

Also in 1958 Carrington et al presented their data of the results of testing for
carbohydrate intolerance in pregnancy and the treatment of women with
abnormalities - a seminal paper which could be considered the forerunner of
modern diagnosis and treatment. Women with high risk pregnancies, with
criteria that are now universally recognised as historical risk factors for GDM,
had a GTT at various stages during pregnancy. Those women with abnormal
results were treated with diet and, in a few instances, with insulin. Those
women diagnosed and treated early had no fetal deaths while those women
who were diagnosed at a late stage or around the time of delivery had an
infant mortality rate of 25.6%. The observation that the "difference between
treated and untreated patients indicate that early diagnosis is important" was
as valid then as it is now.

The term "gestational diabetes" appeared in the authoritative medical
literature in 1961 (O'Sullivan). In a retrospective survey the results of glucose
tolerance testing in 8344 high risk patients delivered between 1954 and 1959
in Boston, USA, were presented. Using diagnostic criteria, which in some
centres is still used today with only minor modifications, the overall incidence
in the women tested was 0.73%. No mention was made of fetal outcome in this
paper. Three years later the validity of the diagnostic criteria for predicting the
conversion to NIDDM were presented (O'Sullivan et al, 1964).

The possibility of an increased perinatal mortality rate associated with GDM
was prospectively addressed in an observational study for the first time in
1973 by O'Sullivan et al. A perinatal mortality rate of 6.4% in 187 pregnancies
complicated by GDM was more than four times the rate of 1.5% in 259 control
patients. In another observational study Pettitt et al (1980) found that the rates
of perinatal mortality, macrosomia, toxaemia and Caesarean section varied
directly with the maternal glucose concentration 2 hours after a 75 g glucose
load administered in the morning without fasting. They concluded that the
"distribution of third-trimester glucose levels were unimodal and continuous"
and therefore it was "not possible to identify a specific level of glucose
intolerance that can be designated as gestational diabetes".

The selected papers outlined above, progressing from retrospective reviews to
the delineation of gestational diabetes and to prospective observational
studies have clearly outlined the extent and seriousness of the problem of
GDM. It would now not be ethically possible to repeat any observational study
unless the glucose level for non-intervention was set at such a low level as to
make any unfavourable fetal outcome extremely improbable. While advances
in obstetric and perinatal management continue to make pregnancy and
childbirth an increasingly low risk event, the lessons from history can only be
forgotten or ignored with extreme peril.

Literature review - Diagnosis of GDM.
There is little consensus about the ideal way of diagnosing GDM. This is due
to methodological differences between the established criteria, difficulties in
determining criteria sympathetic to the fetal outcomeand very real differences
in the glycaemic responses of the populations being tested.

The results of glucose tolerance testing in pregnancy will vary depending on
the period of gestation (Forest et al, 1983; Hatem et al, 1988) the racial group
(Phillipou, 1993) and perhaps the ambient temperature (Schmidt et al, 1994;
Moses et al, 1995). When dealing with fine diagnostic margins between
normality and GDM the GTT has been criticised for a lack of reproducibility
(Catalano et al, 1993).

Current clinical practices regarding testing, screening and the diagnosis of
GDM vary considerably (Nelson - Piercy et al, 1993; Hunter et al, 1990). The
screening tests currently employed use different glucose loads, may be used
fasting or non - fasting, may rely on a one or two hour glucose sample and
have variable cut off points for further testing (Cousins et al, 1991). The
definitive oral GTT, to mention a few, may use the O'Sullivan criteria
(O'Sullivan et al, 1964), the modification of Carpenter and Coustan (Carpenter
et al, 1982), the National Diabetes Data Group (NDDG) criteria ( NDDG,
1979), the WHO criteria (WHO, 1980) or in Australia the Mercy Hospital criteria
(Abell et al, 1975) or the ADIPS criteria (Martin, 1991).

The diagnostic criteria for GDM have concentrated on glucose measurement
for historical reasons, ease of measurement and reproducibility between
laboratories. It is now apparent that variations in insulin sensitivity and insulin
resistance as well as disorders of fat and amino acid metabolism can all be an

intrinsic part of the GDM syndrome (Ratner, 1993). Alternative diagnostic
criteria using amniotic fluid Insulin (Persson et al, 1989) and maternal
glycosylated proteins (Morris et al, 1986) have been suggested. Buchanan et
al (1994) have suggested the use of fetal ultrasound measurements to Identify
higher risk subgroups.

Ultimately the most suitable means of defining a disease must be based upon
the morbidity associated with that condition. The diagnosis of GDM has so far
been almost exclusively based upon measurement of maternal glucose levels.
For practical reasons this is likely to remain the situation for the immediate
future. The maternal glucose level, and the method of testing, which most
accurately defines the risks to the fetus have yet to be determined.

Literature review - The risk to the fetus.
It has becoming increasingly apparent that many adult diseases have their
origins in infancy or as a result of factors operating in the intrauterine
environment. Maternal undernutrition or specifically, protein/calorie
malnutrition, may result in a fetus who is either small for gestational age (SGA)
or who has a disturbance of anthropometry. Excessive fetal nutrition, perhaps
as a consequence of maternal diabetes, may lead to a large for gestational
age (LGA) fetus or a macrosomic fetus with excessive fat accumulation.

Interest in the linkage between ischaemic heart disease and birth weight
became an issue for the first time towards the end of the eighties. Barker et al
(1989a) examined the relationship between birthweight and cardiovascular
mortality in 5654 men born between 1911-1930 in Hertfordshire, England.
Men with the lowest weights at birth (and at one year) had the highest death
rates from cardiovascular disease. In England, past trends in infant mortality,
taken as a surrogate for infant health and nutrition, correlated well with
subsequent trends in ischaemic heart disease (Osmond, 1987). It could be
postulated that the decline in cardiovascular deaths in other Western countries
which began in the sixties could be related more to changes in infant morbidity
at the turn of the century than to subsequent health interventions (Barker,
1989b).

The Hertfordshire report was the first part of an increasing body of
epidemiological evidence linking low birthweights with adult onset
hypertension (Barker et al, 1990), NIDDM (Hales et al, 1991), and high
cholesterol concentrations (Barker et al, 1993). Thinness at birth, either
determined by a low ponderal index or a relative reduction in abdominal
circumference was associated with insulin resistance (Phillips et al, 1994) and
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the features of Syndrome X (Barker et al, 1993).

The epidemiological data outlined above also sit comfortably with the thrifty
gene hypothesis of NIDDM (Hales et al, 1992). A significant impediment to a
more generalised extrapolation of these findings has been the fact that the
results have so far been confined to Caucasians living in one country.
However corroborative data are now becoming available from different ethnic
groups in the USA (Valdez et al, 1994). Animal experiments (Swenne et al,
1987), at least as far as the development of diabetes is concerned, have
suggested that protein-calorie malnutrition may be an important aetiological
factor.

If on one hand reduced fetal nutrition leading to low birthweights can be linked
to serious adult diseases, then on the other hand fetal overnutrition can also
have deleterious effects. Maternal diabetes mellitus, either established before
the pregnancy and poorly managed during the pregnancy, or gestational
diabetes in the last trimester are examples par excellence of this particular
problem. In the Pima Indians the risk of subsequent diabetes was 'U' shaped
with a higher rate for both low and high birthweight infants (McCance et al,
1994). According to the Pedersen hypothesis (Pedersen et al, 1977), elevated
maternal glucose levels cross the placenta and lead to an increased fetal
insulin secretion. Fetal insulin is a potent growth factor and promotes fat
storage of this excessive metabolic fuel resulting in a high rate of macrosomia.
This fuel mediated teratogenesis (Freinkel, 1980) leads to an increased risk of
several childhood, adolescent and adult onset disorders.

Using Wistar rats it has been demonstrated that the degree of fetal islet cell
hyperplasia at birth was correlated with the severity of the maternal diabetes

(Aerts et al, 1977). As young adults the pups born from mothers with diabetes
were often heavier and had impaired glucose tolerance on stimulation
(Bihoreau et al, 1986; Gaugier et al, 1990). The mechanism of this insulin
resistance appeared to vary depending on the severity of the maternal
diabetes (Aerts et al, 1988). Females of the second generation had a high risk
of developing GDM, an observation which led to the question as to whether
GDM was an acquired condition (Aerts et al, 1979). The metabolic
consequences of a pregnancy complicated by GDM can be detected in at
least the third generation (Van Assche et al, 1991).

Prospective long-term longitudinal studies of humans over several
generations are, for obvious reasons, difficult. However the Pima Indians of
Arizona have provided a unique opportunity for the study of GDM because of a
very high prevalence rate of NIDDM and a tendency to develop this condition
at an early age. The Pima Indians thus provide an excellent model for the
study of GDM and the effect of this complication on subsequent generations.

There is a definite genetic tendency towards NIDDM. In the Pima Indians the
risk is significantly higher for a child to develop NIDDM if the mother rather
than the father has had NIDDM (Knowler et al, 1985). In addition, 35% of
patients with GDM are offspring of diabetic mothers and diabetic mothers are
five times more likely than diabetic fathers to have a daughter who develops
GDM (Martin et al, 1985). The data from the Pima Indians also indicate that
there is a profound intrauterine influence in addition to any genetic tendency.
Impaired glucose tolerance at ages 15-19 years is present in 33% of children
whose mother had diabetes during pregnancy compared to 1.4% in children
whose mother developed diabetes after the pregnancy (Pettitt et al, 1988).

In the Pima Indians the probability of a child having impaired glucose
tolerance or being a diabetic increased as the maternal glucose level
increased following a 75g glucose challenge (Pettitt et al, 1991). This
stratification of risk applies even for maternal results which by any criteria are
non-diabetic. Of greatest concern, and of enormous public health importance,
was the finding that those female offspring who had become pregnant had a
prevalence of GDM of 18.8% if their mother's glucose during glucose
tolerance testing in pregnancy was between 5.6-6.6 mmol/L and 50% if their
mother's glucose level was ^7.8 mmol/L but below the level considered
diagnostic of diabetes.
In addition to problems associated with the development of NIDDM and GDM,
the offspring of mothers with GDM also appear likely to have problems with
neuropsychological development and with a lower IQ. This association was
first made apparent by Churchill et al (1969) and later by Rizzo et al (1991).
Thus fetal undernutrition, most likely due to maternal protein/calorie
deprivation, and fetal overnutrition, most commonly associated with maternal
GDM, can lead to adult diseases and problems in subsequent generations.
There appears to be no distinct and definable point of the maternal glucose
level at which these complications develop and a continuum of risk can be
considered to exist (Pettitt et al, 1980). Thus criteria used to define maternal
GDM on the basis of the subsequent risk of the mother developing NIDDM are
most likely inappropriate for the fetal risk during and after pregnancy. With
respect to glucose tolerance testing in pregnancy, there may be at least two
different criteria required for two different areas of risk.

Literature review - What are the effects of minor degrees of glucose
intolerance on fetal and pregnancy outcomes?
The possibility that glucose levels in the mother below the threshold for the
diagnosis of GDM could be a risk factor for a poor pregnancy outcome was
bought into sharp focus by Tallarigo et al (1986). This paper provided the
stimulus for a critical examination of the previous literature and for several
prospective studies.

Tallarigo et al prospectively examined several pregnancy outcomes
(macrosomia, fetal mortality, prematurity, toxaemia and Caesarean section
rates) in 293 prenatal patients over a three year period. These women had
had a standard 100 g GTT (O'Sullivan et al, 1964) at the beginning of the third
trimester and did not have GDM. They were divided into three groups on the
basis of the 2 hour plasma glucose level after the GTT. Group A had a glucose
level ^ 5.6 mmol/L, group B had a glucose level between 5.7 and 6.7 mmol/L
and Group C a glucose level between 6.8 and 9.1 mmol/L.

The macrosomic rate from groups A, B and 0 were 9.9%, 15.5% and 27.5%
respectively while the rate of maternal complications (toxaemia plus
Caesarean section) were 19.9%, 25.9% and 40.0%. The increasing risk with
rising maternal glucose levels could not be explained by either age or body
weight. The women who had macrosomic infants or who had a maternal
complication had significantly higher glucose values than those who did not.

There are, however, some problems with this paper which could detract from
the significance of the findings. Firstly, the type of patients who attend a
prenatal clinic which sees less than 100 patients each year was not defined.

Secondly, macrosomia was defined on the basis of a birthweight ^ 4,000 gms
and was not corrected for gestational age or gender. Thirdly, the combining of
toxaemia and Caesarean sections as an indication of maternal risk is not a
physiological association. Fourthly the women in group C included some who
would now be classified as having GDM by the WHO criteria. The "letter"
criticisms which followed this publication included comments on the statistical
methodology (Mimouni et al, 1987), the laboratory technique for measuring
glucose (Dietrick, 1987), the inclusion of women with poor obstetric histories
(Weiss, 1987), and the failure to adjust fetal birthweight data for the mother's
age and weight (Jarrett, 1987).

Despite these shortcomings and criticisms this paper did provide the
intellectual stimulus for others to examine pregnancy outcomes in women with
glucose levels below the diagnostic criteria for GDM. These papers can be
loosely divided into two groups. The first group, (Li et al, 1987; Weiner, 1988;
Roberts et al, 1993) which are generally cited as evidence that there is no
gradation of risk with increasing maternal glucose levels, examined major
endpoints like mortality and major degrees of morbidity. The second group,
(Pettitt et al, 1980; Tallarigo et al, 1986; Leiken et al, 1987; Langer et al 1989;
Lindsay et al, 1989; Kaufmann et al, 1992) which have generally found an
increase in adverse obstetric outcomes with increasing levels of maternal
glucose, examined softer endpoints such as the rates of macrosomia,
induction and Caesarean section.

In 1987 Li et al from Hong Kong compared the efficacy of the WHO GTT
criteria to the NDDG criteria. As a side issue of this evaluation, some
observations about perinatal outcomes were presented. On the basis of
testing women with historical risk factors for GDM, 245/1546 (16%) had an

abnormal NDDG GTT and 216 subsequently had a WHO GTT. Using the WHO
criteria, 111 women (51%) had normal glucose tolerance (NGTT), 98 (45%)
were impaired (IGTT) and 7 (3%) had diabetes. Those women who had either
a NGTT or an IGTT were divided into a control or treatment group. The authors
felt that the "perinatal outcome in these two groups was comparable" and
whatever differences were apparent "probably have no clinical significance".
This conclusion has been used by others to imply that as treatment produced
no differences, there would appear to be little point in establishing a diagnosis
which appeared not to be relevant.

However there are some difficulties with these conclusions when the
substance of the paper is studied. The patients were selected on the basis of
historical risk factors and ultimately there were relatively low numbers
involved. The women with IGTT who were treated had a lower mean birth
weight, no babies weighing more than 4000 g and only 13% of babies
weighing more than the 90 th centile compared to a rate of 24% in the
untreated control group. No mention was made of the induction rate or the
frequency of assisted deliveries.

Weiner (1988) reported on the outcomes of 312 women with normal glucose
tolerance and included a "control" group of women with GDM. The rationale
for this was that if increasing levels of maternal glucose posed additional risks
to the pregnancy then this should be most pronounced in women with GDM.

Weiner found that if the glucose results of those women without GDM were
ranked, many of the abnormalities only occurred in the highest ranked groups
and thus did not suggest a gradient of risk. Overall there was a positive
correlation between maternal age and the glucose result but no relationship

between birthweight and the maternal glucose result. However there was an
increase In the proportion of mothers who had a baby weighing more than the
90 th centile from 4.4% if the 2 hour glucose level on the GTT was < 100 mg%
(5.6 mmol/L) to 18.4% if the 2 hour glucose level on the GTT was between
140-159 mg% (7.8-8.8 mmol/L). Within the same grouping the pre - eclampsia
rate increased from 4.4% to 10.5%. This study was based upon relatively
small numbers, relative in so far as there would need to be a much larger
group to demonstrate the low probability of major complications like perinatal
death or significant morbidity. The need to include a "control" group of women
with GDM, who were all treated with either diet or a combination of diet and
insulin, to confirm the hypothesis that the risks will continue to increase, was
difficult to understand.

Witter et al (1988) investigated whether the 50 g glucose challenge test was
useful for predicting macrosomia in women without GDM. They came to the
conclusion that minor abnormalities of carbohydrate intolerance are a risk
factor for macrosomia but the result of the glucose challenge test was a poor
predictor of this. The strength of this paper was the large number of patients
examined while the weaknes was that macrosomia was the only outcome
measured.

The final study, which is frequently cited as showing no differences in
pregnancy outcomes for maternal glucose levels below the threshold for GDM
is that of Roberts et al (1993) from Belfast. Over a 47 month period 953 women
selected according to established risk factors for GDM (and representing only
7% of the total obstetric population) had a WHO GTT. One hundred and thirty
five women had an impaired GTT and overall had no difference in the fetal
outcomes selected or neonatal morbidity compared to a control group.

However despite this reassuring conclusion, tine mothers with an impaired
GTT had a significantly higher rate of both induced labour and Caesarean
section.

The papers described above were in general able to conclude that there were
no significant differences related to varying levels of maternal glucose for the
endpoint selected. However if less "major" endpoints had been chosen then
each of the above papers demonstrated adverse obstetric outcomes like
increased risks of macrosomia, induction and Caesarean section associated
with the maternal glucose level. In this respect the above papers differ little
from those which will be reviewed below except that those described below
have looked at a wider and more relevant range of obstetric outcomes.

Pettitt et al (1980) reported on the maternal and fetal outcomes of 811
pregnancies in 604 Pima Indian women who, over a thirteen year period, all
had had a glucose tolerance test during the third trimester. The rates of
perinatal mortality, macrosomia, toxaemia and Caesarean section varied
directly with the glucose concentration. In addition to maternal glucose levels,
maternal age and weight were predictive of both macrosomia and toxaemia.
This study has particular relevance to the patients examined in this thesis
because, in contrast to most American studies, the dose of glucose used was
75 g and only the 2 hour glucose level was considered. For those mothers
with a glucose level at 2 hours of less than 5.6 mmol/L (100 mg%) a
Caesarean section was required in 2.3%, toxaemia developed in 0.2% and
there was a 23.2% rate of LGA infants. For those mothers with a 2 hour
glucose level more than 11.2 mmol/L (200 mg%) the section rate was 14.3%,
toxaemia developed in 62.5% and the rate of LGA infants was 80.0%. The
results in between demonstrated a gradient of risk.

There are some unusual features of the Pima Indians which make these
absolute rates not generally applicable. They are a population who develop
NIDDM with a very high frequency and at a relatively early age. They are also
much heavier than the average American. However the importance of these
figures is not the absolute rates but the definite gradation and increase of risk
with increasing maternal glucose levels.

Langer et al (1989) reported on the results of management in a group of
women with one abnormal result on a glucose tolerance test. It had previously
been demonstrated by both Langer et al (1987) and Lindsay et al (1989) that
women with one abnormal value on a GTT done during pregnancy were more
likely to have a fetus with macrosomia and metabolic complications than
women with no abnormalities on their GTT. Leiken et al (1987) also reported
similar findings and furthermore felt that the risk associated with the maternal
glucose level remained after adjustment for other macrosomic risk factors.
Kaufmann et al (1992) were unable to demonstrate that women with one
abnormal value had a higher rate of LGA after correction of birth weight for
gestational age. The suggestion was made that higher glucose levels may
result in slightly longer gestational period. The observation was also made
that the current NDDG criteria for GDM may be too high for predicting those
women who would have a LGA infant.

The purpose of the 1989 study of Langer et al was to see if intervention in the
group with one abnormal value could reduce neonatal morbidity. All women
had a 50 g glucose challenge test followed in those who were positive by a
100 g glucose load GTT. Glucose values were interpreted according to the

NDDG criteria. There were 126 women with one abnormal value on their GTT
(2 abnormal values being required for the diagnosis of GDM) and they were
randomly divided into two groups. One group continued with their usual diet
while the other group received treatment with diet and/or insulin as if they had
GDM. There were 146 women in a control group who had had a normal GTT.
Of the women with one abnormal value on their GTT, the treated group has a
significant reduction in neonatal metabolic complications and in the number of
large infants compared to the untreated group. There were no significant
differences in pregnancy outcomes between the treated group and the control
group.

What these studies have demonstrated is that women who do not meet the
criteria for GDM but who have one abnormal value on the GTT are at
increased risk of adverse pregnancy outcomes. The adverse outcomes
considered have been the rate of macrosomia, toxaemia and the need for
Caesarean section. The study of Langer et al (1989) demonstrated that
intervention in these women can produce results similar to those women
without any abnormality on glucose tolerance testing.

The studies of Pettitt et al (1980) and Tallarigo et al (1986) differ from those
mentioned above. The observations about potential adverse pregnancy
outcomes were extended to all levels of glucose and suggested a gradation of
risk. The difficulties with these two studies are that Tallarigo et al were dealing
with a relatively small number of patients and, from the information available,
an unusual prenatal clinic arrangement. The study of Pettitt et al was based on
the Pima Indians and information from this group has to extrapolated with
care.

The present study herein reported overcomes some of the methodological
problems in the papers discussed above. The number of patients included is
by far the largest of any series so far reported. The maternal and fetal
outcomes have been assessed across the whole range of maternal glucose
values. A comparison group of women with treated GDM have also included.
All of the papers reviewed above have used diagnostic criteria for GDM that
use higher glucose levels than the ADIPS criteria used for the patients in this
study. Consequently many of the patients with one abnormal value on a GTT
would certainly have been classified as GDM by the ADIPS criteria. Thus the
patients used in this study with a 2 hour glucose level < 8.0 mmol/L would be
considered unequivocally normal by any other criteria and thus should help to
settle the question as to whether there is a gradation of obstetric risk
associated with increasing levels of maternal glucose.

PATIENTS AND METHODS

This study was carried out in tine lllawarra area of New Soutli Wales. Data
were collected from the prenatal clinics at Wollongong and Shellharbour
hospitals and from cooperating obstetricians.

Methods: Diagnosis.
The diagnosis of GDM was based on the recommendations of the
Australasian Diabetes in Pregnancy Society (ADIPS) (Martin, 1991). ADIPS
specified that a definitive diagnosis of GDM was to be made after the
administration of a WHO standard GTT at the beginning of the third trimester.
The WHO GTT requires the administration of 75 g of anhydrous glucose in
300 mis of water in the morning after an overnight fast with venous samples
taken fasting and at two hours. GDM is diagnosed if the fasting plasma
glucose is ^ 5.5mmol/L and/or the two hour plasma glucose level is ^ 8.0
mmol/L.

Some patients in this study had a GTT and some had a modification of the
GTT (MGTT). With the MGTT the standard WHO GTT was used but only the
two hour sample was collected (Moses, 1992). The ADIPS criteria of a two
hour plasma glucose ^ 8.0 mmol/L was used for diagnosis.

Glucose samples were processed in air conditioned premises either by the
biochemistry department of Wollongong hospital or by two private pathology
companies. Laboratory standards were comparable as each performed
satisfactorily on national Quality Assurance programs for all routinely
measured analytes including glucose. The venous sample for plasma glucose
was collected fasting and/or at two hours, immediately separated after

collection and stored at 40C until analysed. Analysis was done by Wollongong
hospital using a glucose oxidase method on a Kodak Ecktachem 700XRC
(Rochester, USA). Analysis was done by the pathologists in private practice
using a hexokinase method on an Olympus REPLY (Tokyo, Japan).

Methods: Data collection procedures
For the first six months of 1993 the prenatal clinic at Wollongong Hospital
offered the MGTT to all women while the prenatal clinic at Shellharbour
Hospital offered all patients a GTT. From July 1993, and for the remainder of
the period of data collection, this situation was reversed. Only those prenatal
clinic patients who were screened during 1993, and who had delivered by the
end of April 1994, have been included.

Additional data were obtained from two specialist obstetricians and a general
practitioner with an interest in obstetrics who offered a MGTT to all of their
patients from the beginning of 1993. A third obstetrician agreed to collect data
from the beginning of 1994. The patient data from these sources were all
women who were tested until the end of February 1994.

Data collection at the Wollongong Hospital was done by a midwife working in
the prenatal clinic. After a short evaluation period, a system of data collection
suitable for the procedures and staff at Wollongong Hospital was introduced.
Data collection at Shellharbour Hospital was done by a midwife working in the
Labour Ward who examined the prenatal clinic records several times each
week. It was not possible at Shellharbour Hospital for information about
previous GDM or whether there was a positive family history of diabetes in a
first degree relation to be obtained. Both midwives were on a monthly retainer.

Data collection by the private obstetricians was collated by their staff using a
standardised system. Data about previous GDM and a family history of
diabetes was not practicable to collect. The general practitioner collected all
data herself.

Methods: Pregnancy and fetal outcome data.

Pregnancy and fetal outcome details were obtained from the NSW Midwives'
Data Collection Form. It is a requirement of the NSW Department of Health
that this form be completed by staff at the hospital from which the mother was
eventually discharged after the completion of the pregnancy. In the lllawarra
area this was Wollongong Hospital, Sheilharbour Hospital or The lllawarra
Hospital. The lllawarra Hospital is a private hospital where some private
patients were transferred to after delivery. Parts of the Midwives' form were
completed by the Labour Ward staff after delivery and the balance by the staff
of the obstetric wards.

It was not logistically possible to obtain the required data from the the
Midwives' forms at the time of discharge from hospital. The Midwives' forms
were obtained from the respective Medical Records Departments at a later
date during the process of coding. The Medical Record Departments did not
have the resources available to search for and present all of the Midwives'
forms to match all of the patients who had had glucose tolerance testing.
During the coding process the Midwives' forms were set aside, collected by
myself on a regular basis and copied for future data entry. Dependent on the
generosity of the Medical Records Departments, it was not practicable to ask
for details of those patients whose forms did not become available by these
means. However there was no reason to believe that the forms of any patients
were held back or were dealt with in any manner which would not have made
them available.

All data were stored on a Macintosh LC using Statview (Abacus Concepts,
Berkeley, California).

Methods: Data collection - tvoe and definitions.
The maternal data collected included name, the month and year at which the
glucose tolerance testing was done, the hospital or obstetrician responsible
for the care, the age of the patient when tested, parity, preconception weight
by recall, height, the ethnic background of the mother, the number of weeks
gestation at which the glucose tolerance testing was done, whether the
procedure was a GTT or a MGTT and the glucose result fasting and at 2
hours. Body Mass Index (BMI) was calculated by dividing the preconception
weight in Kg by the height in metres squared.

The information required for this survey from the Midwives' form included the
following; whether there was Pregnancy Induced Hypertension and
gestational diabetes; whether labour was spontaneous or induced; the
method of delivery; whether the fetus was alive or dead; fetal gender; plurality;
birthweight in grams; gestational age at delivery; Apgar score at 10 minutes;
neonatal morbidity. The Apgar score is an index used to evaluate the
condition of the newborn infant with a rating of 0 - 2 for each of the following
five characteristics; colour, heart rate, response to stimulation of the sole of the
foot, muscle tone and respiration.

Ethnic background. The mother's country of birth was recorded and grouped
into geographical areas; Australasia (Australia, excluding aboriginals, and
New Zealand), northern Europe, southern Europe, Asian, Indian, Aboriginal,
Pacific Islanders and others. Because of small numbers the ethnic groups of
Asian, Indian, Aboriginal, Pacific Islanders and "others" have been
presented in the Results section as "others". Women were classified as
Southern European if they came from a country with a border on the
Mediterranean Sea.

Pregnancy induced Hypertension fPIHV The presence or absence of this
complication was obtained from the Midwiyes' Data Form.
Induction. This information was obtained from the Midwiyes' Data Form.
Labour was either spontaneous or induced. The different types of induction
were not distinguished. Those women who had an electiye Caesarean
section were excluded from this section.

Method of deliyery. This information was obtained from the Midwiyes' Data
Form. The different methods of deliyery were; spontaneous yaginal, forceps
assisted, yacuum extraction, electiye Caesarean section and emergency
Caesarean section.

Neonatal morbidity. This information was obtained from the Midwiyes' Data
Form. "Morbidity" was defined as the need for a baby to be admitted to a
special care nursery. This facility was only ayailable at Wollongong hospital
and thus deliyeries at Shellharbour hospital were excluded.

Methods: Exclusions.
The primary exclusions from this survey were those patients whose Midwives'
Data Form was not available using the means of collection mentioned above.
Data on patients were included if they had been tested after 24 weeks of
gestation, delivered after 32 weeks of gestation and had had a singleton live
fetus.

With diverse people responsible for completing the Midwives' forms there
were inevitably some clerical omissions. Fetal birthweight was available on an
estimated 99% of all forms. After the exclusions mentioned above, only those
patients who had the fetal birthweight recorded were used for the survey.
Inevitably a small amount of some of the other data were incomplete.

Methods: Statistical methods.
Unless specified otherwise, results have been expressed as a percentage or
as a mean with one standard deviation in parentheses. The statistical
methods used included the two-sample pooled t - test, Chi-squared analysis,
multiple regression analysis and logistic regression analysis. Unless
otherwise stated the result of the 2 hour glucose level after the GTT (gtt2) in
the contingency tables have been presented in the following groups; ^ . 9 ,
4.0 - 4.9, 5.0 - 5.9, 6.0 - 6.9, 7.0 - 7.9 and, for women with GDM, as ^ 8.0
mmol/L respectively. The fasting glucose level (gttO) was available in 389
instances. Unless otherwise stated the gttO data were arranged in the
contingency tables in the following groups; ^3.9, 4.0-4.1, 4.2-4.3, 4.4-4.5
and ^ 4 . 6 mmol/L respectively.

In order to determine at what level of gtt2 the risk of non-GDM mothers
experiencing a particular characteristic (eg, non-vaginal delivery) would be
equivalent to the risk experienced by the treated GDM mothers, the following
calculation was used. Each risk was transformed by converting it to equivalent
odds. When the risk for a particular event for GDM mothers was within the
range of risks for non-GDM mothers, the odds of having this condition could
be modelled by logistic regression in which the gtt2 was used as the predictor.
As will be shown in the Results section, this situation only applied to large for
gestational age infants (LGA) and pregnancy induced hypertension (PIH).

For example, for GDM mothers the odds of having PIH is 16/108. The log of
these odds is - 1.9095. The equation which predicts the odds of PIH in terms
of gtt2 for non-GDM mothers is log (odds) = -3.5253 + 0.2065 x gtt2. If - 1.9095
is set equal to - 3.5253 + 0.2065 x gtt2, then the value of gtt2 can be found
which makes these equal.

All analyses were conducted on the University of Wollongong's SUN 4/470
mainframe computer, using the statistical package SAS Institute, Inc, Box
8000, Gary, NC, USA 27511-8000. Some analyses were checked using the
statistical package Genstat, which is produced by the Numerical Algorithms
Group Ltd, Mayfield House, 256 Banbury Road, Oxford, United Kingdom 0X2
7DE.

Methods: Ethical approval.
Ethical approval for this research was provided by the Human Research
Ethics Committee of the lllawarra Area Health Service and the University of
Wollongong.

RESULTS
Data were available on 1441 normal pregnancies and 125 pregnancies in
women with GDM who had had a singleton live fetus. The gender of the fetus
was recorded in all but two instances and males comprised 51.0% of the total.
A GTT was done in 388/1441 (26.9%) cases and a MGTT in 1053/1441
(73.1%) cases.
Maternal demographic, obstetric and birthing details for all of the normal
women by different ethnic groups are shown in table 1.

Table 1.
Maternal demographic, obstetric and birthing details according to the ethnic
origin - mean (1SD).
Australasian

N. European

8. European

Others

n=1062

n=126

n=115

n=115

Age in years

27.2 (5.0)

28.1 (4.7)*

26.9 (4.7)

27.6 (5.6)

Parity

0.9 (1.0)

0.9 (1.0)

1.0 (1.2)

0.9 (1.2)

BIVII (Kg/m2)

23.9 (4.6)

23.9 (4.6)

24.7 (4.7)

22.8 (4.6) *

Week of test

28.0 (1.9)

28.4 (2.0) *

27.50(1.9) **

28.2 (2.1)

gtt2 (mmol/L)

5.6 (1.0)

5.7 (1.0)

5.7 (1.0)

5.8 (1.1)*

Birthweight (g)

3448 (519)

3420 (519)

3412 (451)

3394 (482)

Gest. age (weeks)

39.5 (1.4)

39.5 (1.4)

39.6 (1.3)

39.3 (1.4)

*p<0.05, ** p<0.01.

The women of Northern European origin were significantly older and the
women in the "others" group (mainly Asian) had a significantly lower
preconception BMI. The number of women from different ethnic groups were
relatively small compared to the Australasian group and therefore only the
total number has been subsequently used for data analysis.

Maternal demographic, obstetric and birthing details for the normal women
according to the maternal gtt2 level are shown in table 2.

Table 2.
Maternal demographic, obstetric and birthing details for normal women
according to the maternal gtt2 level - mean (1SD).

Maternal glucose Age
(mmol/L)
^ 3.9 mmol/L

Parity

(years)

BMI

Birth weight

Gest. age

(Kg/m2)

(grams)

(weeks)

28.2 (3.8)

1.0 (0.9)

22.3 (3.2)

3308 (487)

39.2 (1.6)

27.1(5.0)

0.9(1.0)

23.2 (4.0)

3403 (504)

39.5 (1.5)

27.0 (4.9)

0.9 (1.0)

23.7 (4.6)

3452 (480)

39.6 (1.3)

27.4(5.1)

0.9(1.0)

24.7 (5.0)

3462 (522)

39.6 (1.4)

28.3 (5.3)

0.7 (1.0)

24.5 (4.9)

3471 (624)

39.5(1.5)

n = 83
4.0 - 4.9 mmol/L
n = 291
5.0-5.9 mmol/L
n = 561
6.0-6.9 mmol/L
n = 363
7.0-7.9 mmolL
n = 142

Maternal demographic, obstetric and birthing details for the total of all normal
(non-GDM) women and the GDM mothers are shown In table 3.
Table 3.
Maternal demographic, obstetric and birthing details for the total of non-GDM
mothers and for GDM mothers - mean (1SD).

Total non-GDM
n = 1441.

GDM
n = 125.

Age In years

27.3

(5.0)

29.1

(5.2)

Parity

0.9

(1.0)

0.8

(1.0)

BMI (Kg/m2)

23.8

(4.6)

26.0

(5.7)

Week of test

28.0

(2.0)

28.1

(1-9)

gtt2 (mmol/L)

5.6

(1.1)

8.9

(1.6)

Birthweight (g)

3438 (512)

Gest. age (weeks)

39.5

(1.4)

3402 (477)
39.3

(1.4)

* p < 0.0001

The women with GDM were significantly older, had a higher preconception
BMI and a higher (by definition) gtt2 level. There were no differences with
respect to parity, birthweight and the gestational age of delivery.

Results: Frequency of assisted delivery.
Deliyeries were classified as normal yaginal or assisted (forceps, yacuum
extraction, elective Caesarean section or emergency Caesarean section).
Table 4.
Percentage of normal vaginal and assisted deliveries according to the
maternal gtt2 level.
Maternal glucose

normal vaginal %

assisted %

total

^3.9mmol/L

86.1

13.9

(n = 79)

4.0-4.9 mmol/L

76.7

23.3

(n = 283)

5.0-5.9 mmol/L

77.7

22.3

(n = 548)

6.0-6.9 mmol/L

72.5

27.5

(n=353)

7.0-7.9 mmolL

69.6

30.4

(n = 138)

^ 8 . 0 mmol/L

66.9

33.1

(n = 121)

A Chi-squared analysis of contingency tables (for non-GDM mothers only) was
used to examine whether the proportions of normal vaginal and assisted
deliveries for non-GDM mothers were the same for each category of gtt2.
There was a significant association between the level of gtt2 and the
proportion of deliveries which were assisted (X2=10.799, df. = 4. p = 0.029).
The tendency was for the proportion of assisted deliveries to increase as the
gtt2 increased.

The mean gtt2 levels were examined using a two-sample pooled t - test to see
whether a significant difference existed between those mothers who had or

had not had an assisted delivery. An assisted delivery was performed in
358/1421 (25.2%) of mothers who had a mean gtt2 level of 5.8 (1.0) mmol/L.
This was significantly higher than the mean gtt2 level of 5.5 (1.0) mmol/L for
the 1063/1421 (74.8%) mothers who did not have an assisted delivery (t =
4.941. df. = 1419, p = 0.0001).

The logistic regression predicted equation for the odds that a birth would be
an unassisted vaginal were logit(p) = -3.4481 - 0.0434 x BMI - 0.0694 x age +
0.5302 X parity + 0.2047 x gestational age - 0.1646 x gtt2.

Each of the variables BMI (p < 0.01), mothers age (p < 0.01), parity (p < 0.01),
gestational age of delivery (p < 0.01) and gtt2 (p < 0.02) were statistically
significant in the presence of the others.

The odds in favour of a normal vaginal delivery are estimated to increase by
69.9% for each increase of one in the parity and by 22.7% for each advancing
week of gestational age. The odds in favour of a normal vaginal delivery are
estimated to decrease by 4.3% for each one unit increase in BMI, by 6.7% for
each year increase in mothers age, and by 15.2% for each 1.0 mmol/L
increase in gtt2.

The risk that a delivery for a GDM mother was assisted was outside the risks
for non-GDM mothers. Hence it was not feasible to estimate the value of gtt2
which made the risk for non-GDM mothers equal to the risk for a GDM mother.

The various types of assisted deliveries were examined separately and are
presented in table 5. It was necessary to pool the two gtt2 categories of ^ 3.9

and 4.0-4.9 to provide sufficient numbers for analysis.

The Chi-squared test was used for non-GDM mothers only to test the null
hypothesis that the relative proportions of the various types of deliveries were
the same across the various levels of gtt2. The Chi-squared test suggested
that the relative proportions were not constant (X2 = 22.658, df. = 12, p =
0.0308). This came about because the number of forceps assisted deliveries
and emergency Caesarean sections were larger than expected in the
category 7.0-7.9 mmol/L and the number of emergency Caesarean sections
were less than expected for gtt2 levels in the category 5.0-5.9 mmol/L.

Table 5.
Percentage of normal vaginal and different assisted deliveries according to
the maternal gtt2 level.
Maternal glucose Vaginal

^ 4 . 9 mmol/L

Forceps

Vacuum

Elective

Emerg.

Caesar

Caesar

78.7

1.4

5.3

7.5

7.2

77.7

2.2

7.3

6.9

5.8

72.5

2.0

6.8

9.6

9.1

69.6

5.8

4.4

8.0

12.3

67.7

3.9

9.5

11.0

7.9

n = 362
5.0-5.9 mmol/L
n = 548
6.0-6.9 mmol/L
n = 353
7.0-7.9 mmolL
n = 138

^ 8 . 0 mmol/L
n = 121

The mean gtt2 levels were examined using a two-sample pooled t - test to see
whether a significant difference existed between those mothers who had, or

had not, undergone Caesarean section (elective and emergency). A
Caesarean section was performed in 217/1441 (15.1%) of mothers who had a
mean gtt2 level of 5.8 (1.0) mmol/L. This was significantly higher than the
mean gtt2 level of 5.6 (1.0) mmol/L for the 1224/1441 (84.9%) mothers who
did not have a Caesarean section (t = 3.0078, df. = 1439, p = 0.0027).

There were 377 women who had a gttO level < 5.5 mmol/L. There was no
significant association between the gttO level and whether the delivery was
vaginal or assisted (X2 = 7.480, df. = 4, p = 0.113). There was also no
significant association between the gttO level and the method of assisted
delivery (X2 = 9.122, df. = 8, p = 0.332).

Results: Parity
With respect to Caesarean sections, a previous section for any reason is likely
to result in a subsequent section. The following contingency table outlines the
rates of elective and emergency section with parity.

Table 6.
Percentage of selected deliveries and maternal parity.

parity = 0

parity ^ 1

total

non-Caesar

40.0 %

60.0 %

(n = 1183)

Elect. Caesar

22.7%

77.3%

(n = 110)

Emer. Caesar

69.2 %

30.8 %

(n = 107)

This table demonstrates a significant association (X2 = 50.805, df. = 2, p <
0.001) between parity and the type of section. Of those women who had a
Caesarean section, women in their first pregnancy were far more likely to have
an emergency section while women in their second and subsequent
pregnancy were more likely to have an elective section.

There were 118 normal women who had a Caesarean section and who had
had two or more pregnancies. Data about previous deliveries were available
in 116 women of whom 79 (68.1%) had had a previous section while 37
(31.9%) had not. There were 13 women with GDM who had a Caesarean
section and who had had two or more pregnancies. Of these 13 women 7
(53.8%) had had a previous section while 6 (46.2%) had not.

Results: Pregnancy induced hypertension (PIH).
The percentage of women with PIH according to their gtt2 leyel are shown in
table?.
Table 7.
Percentage of women with PIH according to the maternal gtt2 leyel.
Maternal glucose

no PIH

PIH

total

^ 3.9 mmol/L

92.8

7.2

n = 83

4.0-4.9 mmol/L

91.7

8.3

n = 290

5.0-5.9 mmol/L

93.4

6.6

n = 562

6.0-6.9 mmol/L

89.3

10.7

n = 363

7.0-7.9 mmolL

86.6

13.4

n = 142

^8.0mmol/L

87.1

12.9

n = 121

The proportion of mothers suffering from PIH increased as the gtt2 leyel
increased though with the Chi-squared analysis for the non-GDM mothers this
trend did not quite reach significance (X2 = 9.304, df. = 4, p = 0.054). Howeyer
the mean gtt2 leyels of the 125/1440 (8.7%) mothers who did haye PIH at 5.8
(1.1) mmol/L was significantly higher than the mean gtt2 leyels of the
1315/1440 (91.3%) mothers who did not haye PIH at 5.6 (1.0) mmol/L (t =
2.2497, df. = 1438. p = 0.0246).

There was no significant association between the gttO leyel and the rate of
PIH (X2 = 1.540, df. = 4. p = 0.820).

The logistic regression predicted equation for the odds of pregnancy induced
hypertension were logit(p) = 6.1764 + 0.1074 x BMI - 0.5654 x parity - 0.2940

X gestational age + 0.1343 x gtt2.

Each of the variables BMI (p < 0.01), parity (p < 0.01) and gestational age of
delivery (p < 0.01) were statistically significant in the presence of the others.
The variable gtt2 was not statistically significant.

The odds in favour of PIH are estimated to increase by 11.9% for each
increase of one unit in BMI. The odds in favour of PIH are estimated to
decrease by 25.3% for each one week increase in gestational age and by
44.1% for each increase of one in parity.

Non-GDM women with a gtt2 of ^ 7.8 mmol/L had a risk for PIH which
exceeded the risk for treated GDM women.

Results: Rate of induction.
Labour was eitlier classified as spontaneous or induced. Those women who'
had an elective Caesarean section have been excluded.

Table 8.
Percentage of women who were induced according to their maternal gtt2
level.
Maternal glucose

no induction %

induced %

total

^3.9mmol/L

76.3

23.7

(n = 80)

4.0-4.9 mmol/L

70.6

29.4

(n = 265)

5.0-5.9 mmol/L

81.2

18.8

(n = 522)

6.0-6.9 mmol/L

76.2

23.8

(n=327)

7.0-7.9 mmolL

75.4

24.6

(n = 130)

^ 8 . 0 mmol/L

62.7

37.3

(n = 110)

A Chi-squared analysis of the contingency table for non-GDM mothers
revealed a significant association of the gtt2 level with the rate of induction (X2
= 11.796, df = 4, p = 0.019). However as can be seen from the table, the
percentage of induced births for mothers does not trend upwards with the level
of gtt2. The rate of induction for mothers with gtt2 levels ^ 3.9 or ^ 6.0 mmol/L
are fairly constant and between 23 and 24%.For those mothers whose gtt2
level is 4.0-4.9 mmol/L the percentage of births induced is 29.4% while for
those mothers with a gtt2 level of 5.0-5.9 mmol/L the rate falls to 18.8%. There
was no significant association between the gttO level and whether the labour
was induced (X2 = 6.184, df. = 4, p = 0.186).

The logistic regression predictive equation for the odds that a birth would be
induced are logit(p) = -12.7454 + 0.0533 x BMI + 0.0312 x age - 0.1922 x
parity + 0.2574 x gestational age - 0.1328 x gtt2.

Each of the variables BMI (p < 0.01), mothers age (p < 0.02), parity (p < 0.02),
gestational age of delivery (p < 0.01) and gtt2 (p < 0.05) were statistically
significant in the presence of the others.

The odds in favour of an induced birth are estimated to increase by 6.2% for
each increase of one in the BMI, by 3.7% for each increase of one year in the
mother's age and by 23.0% for each week in gestational age. The odds in
favour of an induced birth are estimated to decrease by 16.9% for each one
unit increase in parity and by 12.7% for each 1.0 mmol/L increase in gtt2.

Results: Birthweiaht of the babv.
The birthweights were considered in both absolute and relative terms.

Birthweiaht in absolute terms.
In absolute terms a birthweight of ^ 2,500 g was called small for gestational
age (SGA) while a birthweight of ^ 4,000 g was called large for gestational
age (LGA) irrespective of the gender or the gestational age of delivery.

Table 9.
Percentage of absolute SGA and LGA according to the maternal gtt2 level.
Maternal glucose

SGA %

LGA %

total

^ 3.9 mmol/L

6.0

6.0

(n = 83)

4.0-4.9 mmol/L

4.5

12.4

(n = 291)

5.0-5.9 mmol/L

2.1

12.8

(n = 562)

6.0-6.9 mmol/L

3.6

13.5

(n = 363)

7.0-7.9 mmolL

4.9

15.5

(n = 142)

^8.0mmol/L

0.8

10.5

(n = 124)

The Chi-squared test of the contingency table did not suggest for non-GDM
mothers a significant association between gtt2 level and the percentage of
babies who were either SGA or LGA (X2 = 8.302, df. = 4, p = 0.0811). There
was also no significant association for non-GDM mothers between the gttO
level and the percentage of babies who were either SGA or LGA (X2 =
14.706, df. = 4, p = 0.065). There were no significant differences in the LGA
rate for treated women with GDM (13/124, 10.5%) and the non-GDM women

(184/1441, 12.8%) and for the SGA rate for treated women with GDM (1/124,
0.8%) and the non-GDM women (50/1441, 3.5%).

A baby weighing ^4500 g was found in 29/1441 (2.0%) of the non-GDM
pregnancies. The rates did not differ significantly for the maternal gtt2 groups
which were 2/83 (2.4%) for gtt2 ^ 3.9 mmol/l, 4/291 (1.4%) for gtt2 4.0-4.9
mmol/L, 11/562 (2.0%) for gtt2 5.0-5.9 mmol/L, 7/363 (1.9%) for gtt2 6.0-6.9
mmol/L and 5/142 (3.5%) for gtt2 7.0-7.9 mmol/L. Three of the one hundred
and twenty four (2.1%) women with treated GDM had an infant weighing ^
4500g.

The mean gtt2 level of the 184 mothers who had a LGA baby was 5.8 (1.0)
mmol/L which was significantly higher than the mean gtt2 level of 5.6 (1.0)
mmol/L for the 1207 women who had a baby > 2,500 g and < 4,000 g (t =
2.436, df 1390, p < 0.02). The mean gtt2 level of the 50 mothers who had a
SGA baby was 5.6 (1.2) mmol/L which was not significantly different to the
women with a baby > 2500 g and < 4000g.

In absolute terms the odds that a baby would be large for its gestational age
were modelled in terms of the BMI, age of the mother, gtt2 and the gestational
age of delivery. The influence of maternal age and gtt2 were found not to be
significant (p >0.1). When just BMI and gestational age were fitted, both were
significant (p < 0.001). The odds in favour of a LGA baby are estimated to
increase by 7.5% for an increase of one unit of BMI and by 61.2% for each
week of gestational age.

The odds that a baby would be small for its gestational age were modelled in
terms of the BMI, age of the mother, gtt2 and the gestational age of delivery.

The influence of BMI, mothers age and gtt2 were not found to be significant (p
>0.1). The variable gestational age explained the odds to a significant extent
(p < 0.001). The odds in favour of a SGA baby are expected to decrease by
63.7% for each increase of one week in gestational age.

The estimated value of gtt2 for which the risk of a non-GDM mother having a
LGA baby in absolute terms was equal to the risk of a treated GDM mother
was 4.4 mmol/L.

Birthweiqht in relative terms.
Sufficient data was available for deliveries between 37 and 42 weeks
inclusive to calculate birthweight centiles based upon gender and the
gestational age of delivery. In relative terms SGA and LGA were based on the
tenth and ninetieth centiles respectively.
Table 10.
Percentage of relative SGA and LGA according to the maternal gtt2 level.
Maternal glucose

<10 th centile %

> 90 th centile %

total

^3.9mmol/L

13.3

6.7

(n = 75)

4.0-4.9 mmol/L

13.3

8.1

(n = 271)

5.0-5.9 mmol/L

9.0

11.6

(n = 533)

6.0-6.9 mmol/L

10.9

10.6

(n = 341)

7.0-7.9 mmolL

8.4

13.7

(n = 131)

^ 8 . 0 mmol/L

5.9

11.0

(n = 118)

The Chi-squared test of the contingency table did not suggest for non-GDM
mothers a significant association between gtt2 level and the percentage of
babies who were either SGA or LGA in relative terms (X2 = 8.528, df. = 4, p =
0.0740). There was no significant association between the gttO level for nonGDM mothers and the percentage of babies who were either SGA or LGA in
relative terms (X2 = 10.219, df. = 8, p = 0.250). There were no significant
differences in the LGA rate for treated women with GDM (13/118, 11.0%) and
the non-GDM women (143/1441, 9.9%) and for the SGA rate for treated
women with GDM (7/118, 5.9%) and the non-GDM women (144/1441, 10.0%).

The mean gtt2 level of the 143 mothers who had a LGA baby was 5.8 (1.0)
mmol/L which was significantly higher than the mean gtt2 level of 5.6 (1.0)
mmol/L for the 1066 women who had a baby neither SGA nor LGA (t = 2.415,
df 1253, p < 0.02). The mean gtt2 level of the 142 mothers who had a baby
SGA was 5.5 (1.1) mmol/L which was not significantly different to the women
with a baby neither SGA nor LGA.

In relative terms the odds that a baby would be LGA were modelled in terms of
the BMI, age of the mother and the gtt2 result. The influence of the gtt2 level
was not significant (p >0.1). When just BMI and mothers age were fitted both
were significant (p < 0.001 for BMI and p < 0.002 for mother's age). The odds
in favour of a LGA baby are estimated to increase by 9.6% for each increase of
one unit in BMI and by 6.0% for each year in mother's age.

The odds that a baby would be small for its gestational age were modelled in
terms of the BMI, mothers age and the gtt2 level. The influence of age and the
gtt2 level were not significant (p >0.1). When just BMI was fitted, it was
significant (p < 0.001). The odds in favour of a SGA baby are expected to
decrease by 8.3% for each increase of one unit in BMI.

The estimated value of gtt2 for which the risk of a non-GDM mother having a
LGA baby in relative terms was equal to the risk of a treated GDM mother was
5.9 mmol/L.

Results: Aoaar score.
The following contingency table shows the level of gtt2 in the mother and the
Apgar score for the baby. In order to obtain sufficient babies in each column of
the table, those babies with scores between 0 and 6 were grouped into one
category.

Table 11.
Percentage of babies with different Apgar scores according to the maternal
gtt2 level.
Apgar score
8

0-6

10

Maternal glucose
^ 3.9 mmol/L

0.0

1.2

4.8

38.5

55.4

2.0

1.7

4.5

40.6

51.1

1.6

2.7

6.1

41.4

48.3

2.2

3.3

4.2

43.1

47.2

2.1

2.1

6.4

38.3

51.1

0.0

3.2

5.7

47.6

43.6

n = 83
4.0-4.9 mmol/L
n = 288
5.0-5.9 mmol/L
n = 561
6.0-6.9 mmol/L
n = 360
7.0-7.9 mmolL
n = 141
^ 8.0 mmol/L
n = 124

A Chi-squared analysis of the contingency table for mothers without GDM
suggested that there was no association between gtt2 and the Apgar score
(X2 = 8.792, df. = 16, p = 0.922). There was also no significant association with
gttO (X2 = 18.025. df. = 16, p = 0.322).

Results: Mnrhiriity
The following table displays the percentage of babies with "morbidity"
according to the gtt2 level. Deliveries at Shellharbour hospital have not been
included as there was no special care nursery available.
Table 12.
Percentage of babies who were admitted to the special care nursery and thus
deemed to have "morbidity" according to the maternal gtt2 level.
Maternal glucose

no "morbidity"

"morbidity"

total

^ 3.9 mmol/L

76.0

24.0

(n = 75)

4.0-4.9 mmol/L

71.6

28.4

(n = 257)

5.0-5.9 mmol/L

71.3

28.7

(n = 506)

6.0-6.9 mmol/L

67.0

33.0

(n = 330)

7.0-7.9 mmolL

63.2

36.8

(n = 133)

^ 8.0 mmol/L

32.2

67.8

(n = 115)

The Chi-squared analysis of the contingency table for non-GDM mothers did
not suggest any significant association of the level of gtt2 and "morbidity" (X2 =
6.356, df. = 4, p = 0.174). There was also no significant association with the
gttO level (X2 = 4.997, df. = 4, p = 0.288)

The 394 (30.3%) mothers who had a baby with "morbidity" had a mean gtt2
level of 5.8 (1.1) mmol/L which was significantly higher than the mean gtt2
level of 5.5 (1.0) mmol/L for the 907 (69.7%) mothers whose baby did not have
this complication (t = 3.54, df. = 1299, p < 0.001).

As it was conventional practice to admit to the SCN tine babies of mothers who
had had an assisted delivery, the results of those mothers who were "Yes" for
morbidity were further analysed. With respect to unassisted deliveries,
morbidity was present in 8/65 (12.3%) of mothers with a gtt2 level ^ 3.9, in
26/210 (12.4%) of mothers with a gtt2 level 4.0 - 4.9, in 65/426 (15.3%) of
mothers with a gtt2 level 5.0 - 5.9, in 38/259 (14.7%) of mothers with a gtt2
level of 6.0 - 6.9 and in 21/104 (20.2%) of mothers with a gtt2 level of 7.0 - 7.9
mmol/L respectively. With respect to unassisted deliveries, the mean gtt2 level
of 5.7 (1.1) mmol/L of the 161 mothers who were "Yes" for morbidity was
significantly higher than the 5.5 (1.0) mmol/L of the 791 mothers who were
"No" for morbidity (p < 0.02).

The logistic regression predicted equation for the odds of morbidity were
logit(p) = 8.4821 + 0.0340 x BMI - 0.2867 x gestational age + 0.2036 x gtt2.
Each of the variables BMI (p < 0.02), gestational age of delivery (p < 0.01) and
gtt2 (p < 0.01) were statistically significant in the presence of the others.
The odds in favour of being rated "Yes" for morbidity are estimated to increase
by 3.5% for each one unit increase in BMI and by 22.6% for each unit in gtt2.
The odds in favour of being rated "Yes" for morbidity are estimated to
decrease by 24.9% for each one week increase In gestational age.

DISCUSSION.

Data were available on 1.441 normal pregnancies representing about half of
all the deliveries in the lllawarra area during the time of the survey. There is no
reason to suppose that the women included in this study were in any way
different to the overall local obstetric population. When grouped according to
their gtt2 result the women who had a glucose ^ 3.9 mmol/L and between 7.0
and 7.9 mmol/L were significantly older than the other women. There was no
apparent reason for this and adjustments for this were made in the logistic
regression analysis. The mean BMI rose progressively from 22.3 in women
with a gtt2 result ^ 3.9 mmol/L to 24.5 in women with a gtt2 result of 7.0 - 7.9
mmol/L and there was also a progressive increase in mean birthweight from
3308 gm to 3471 gm. The women with a gtt2 result of ^ 3.9 mmol/L had a
slightly lower gestational age of delivery compared to the other groups which
were otherwise very similar to each other.

There were 125 women diagnosed with GDM of whom 110 were cared for by
one person (RM) and treated in a standard way (Moses, 1994b). The overall
incidence of GDM was 8.0% which was similar to an earlier report from the
lllawarra area (Moses et al, 1994a) which used some of the patients included
in this series. As could be anticipated the women with GDM were older and
had a higher preconception BMI than the non-GDM mothers. There were no
differences between the GDM women and the normal women with respect to
parity, the number of weeks gestation at which the glucose testing was done,
the mean birthweight of the babies and the gestational age of delivery. These
results reinforce previous observations that parity per se is not a risk factor for
GDM and well controlled women with GDM can proceed to full term.

There is considerable variation in the rate of GDM in women from different
countries (Hadden, 1985) and in women from different ethnic backgrounds in
Australia (Beischer et al, 1991; Moses et al, 1994a). In Australia, Asian women
have a one of the highest rates of GDM but generally have a lower than
average BMI. The normal women in this study did show some differences in
maternal demography when grouped according to ethnic origin. Women from
Northern Europe were slightly older while the "others" group, comprised
mainly of women from Asia, had a lower BMI and a higher gtt2 result.
Unfortunately, even in this large study, there were insufficient women in the
different ethnic groups to determine if any significant differences existed in the
maternal and fetal outcomes studied. The differences in maternal demography
outlined above could be considered of minor clinical significance, and, as
nearly three-quarters of all the women were of Australasian origin, the results
of all the women were grouped and considered as a whole.

With respect to the diagnosis of GDM, and therefore the classification of
women without GDM, the ADIPS recommendation specified either a
preliminary glucose challenge test in the non-fasting state followed by a
definitive two hour GTT in the fasting state or a two hour GTT in the fasting
state used alone.

There are potential and real problems associated with a two stage diagnostic
procedure. A hypertonic glucose solution is unpleasant to take for most
people at any time and is particularly so in pregnancy. The experience of the
first test must inevitably dissuade some from taking the second test with a
consequent reduction in the diagnostic usefulness. No published reports have
so far considered the problem of the "no show". Other researchers in this field,
albeit from developing countries, (C Deerochanawong and P Porcera:

personal communication) have indicated that as many as 40% of patients do
not present for the second glucose test. A two stage diagnostic procedure
must also result in a delay in diagnosis and therefore treatment which, as
pregnancy is a limited event, may have an impact on outcome.

It would therefore appear logical to "screen" and diagnose at the same time
using the GTT. The problem with the GTT is that it is an inconvenient
procedure requiring two venepunctures and at least a two hour presence in a
laboratory collection area. In the lllawarra area, and there is no reason to
suspect that this area is any different from other areas in Australia, there was
some reluctance by obstetricians to test for GDM because of perceptions
about the inconvenience of the procedure to their patients. These concerns
were addressed in two ways. Firstly, a survey was conducted of patients with
GDM (Griffiths et al, 1993) which showed that, after an explanation was
provided about the Importance of screening, pregnant women were not only
willing to have this procedure but expected this to be conducted as an
important part of routine antenatal care. Secondly, a modification of the GTT
(MGTT) was introduced.

The MGTT, which was used for diagnosis in 73.1% of cases was found to be
a convenient testing procedure for the following reasons (Moses, 1992). The
glucose solution, instructions and explanations were provided in the prenatal
clinic or the obstetrician's office making a visit to the laboratory and the need
to make an appointment for the GTT unnecessary. The glucose solution was
drunk at home and the patient presented two hours later for a plasma glucose
test. This test could also be combined with other routine antenatal
investigations. This method of testing was found to be very convenient by the
obstetricians in private practice.

The major criticism of tiiis one test screening/diagnostic procedure was tliat by
not taking tlie fasting sample those women who had an elevated fasting
glucose but a normal two hour glucose would be missed. The logic is
undeniable that the MGTT will therefore underdiagnose the rate of GDM. The
percentage of patients who will be missed is not known for certain but is likely
to be small. It was considered that increased compliance with a simplified
testing procedure would compensate for the possible small number of patients
who might be missed by not doing the fasting sample.

The clinical significance of a woman with a raised fasting glucose level and a
normal two glucose level is doubtful. Concerns about relying on a fasting
sample have recently been raised by the WHO (WHO, 1994) and the fasting
sample has for many years been dispensed with entirely by Pettitt et al (1994)
in their ongoing observational studies of the Pima Indians. For these very
practical reasons I have suggested that it is now time to modify the GTT for the
diagnosis of gestational diabetes (Moses, 1995a).

There have been several recent reports suggesting that the two hour glucose
sample may be elevated at times of high ambient temperatures leading to the
over diagnosis of GDM in summer and a lower rate of diagnosis in winter
(Akanji et al, 1987; Akanji et al, 1991; Schmidt et al, 1994). This possibility of
temperature induced changes in the gtt2 level were specifically examined in
the patients used in this series and no clinically significant effect was found
(Moses et al, 1995b).

Selected aspects of the maternal and fetal outcomes were examined. A higher
rate of most adverse outcomes have generally been found in women with
GDM and it was the purpose of this study to see whether a continuum of risk

existed across the glucose range of normal women.
The result of the fasting glucose level (gttO) was available in nearly 400
normal women. Unlike the gtt2 level to be discussed below, the gttO level did
not appear to be associated with any of the pregnancy outcomes considered.
Specifically, the gttO level was not associated with whether the delivery was
normal vaginal or assisted, the type of assisted delivery, the rate of PIH, the
rate of induction, the Apgar score or morbidity. The gttO level was also not
associated with the percentage of babies who were LGA or SGA in either
relative or absolute terms.

Assisted deliveries are an established part of modern obstetric practice.
Women with GDM have in the past had a higher rate of assisted delivery,
mainly Caesarean section, due to macrosomia and associated problems.
Recently the tight metabolic control of GDM has resulted in very favourable
fetal outcomes with respect to macrosomia and a reduction in the Caesarean
section rate, in some series, to that not significantly different from women
without GDM (Langer et al, 1994; Drexel et al, 1988; Thompson et al, 1994.)
Where the Caesarean section rate for women with GDM is similar to the rate in
normal women, the usual indication for a Caesarean section is a previous
history of a Caesarean section (Jacobson et al, 1989). In the series herein
reported two - thirds of the normal muciparous women having a Caesarean
section had had a previous Caesarean section. For the multiparous women
with GDM who had a Caesarean section more than half had had a previous
Caesarean section. Where the Caesarean section rate remains higher despite
good control of GDM, it is often based on the preference of the obstetrician
and not always on defined obstetric indications (Kitzmiller et al, 1992).

For the normal women the decision about the method of delivery was made by

the obstetrician responsible and there Is no reason to presume that the
possible knowledge of the normal glucose result would have in any way
influenced this decision. The frequency of assisted deliveries increased in
virtually all categories of gtt2 from 13.9% in those women with a gtt2 ^ 3.9
mmol./L to 30.4% in those women with a gtt2 level of 7.0-7.9 mmol/L The
exception to this tend were the women with a gtt2 result of 5.0 - 5.9 mmol/L
who also had the lowest mean age. Women with a gtt2 result of 7.0 - 7.9
mmol/L had the highest rate of both forceps delivery and of emergency
Caesarean section. Overall those women who had an assisted delivery or a
Caesarean section had a significantly higher mean glucose level than the
other women. The odds in favour of a normal vaginal delivery increased very
significantly with increasing parity and increasing gestational age. These
findings were not unexpected as a previously successful vaginal delivery is
likely to result in further successful vaginal deliveries and many interventional
decisions are likely to take place before full term.

In a controlled evaluation Peipert et al (1993) confirmed previous anecdotal
obstetric literature that there was an increased rate of Caesarean section with
advancing age. While different variables were examined as possible
explanations, the carbohydrate status of the women was not tested. In the
normal women herein reported the odds in favour of an assisted delivery
increased a small amount for each increase in BMI and maternal age.
However the odds in favour increased by 15.2% for each increase of 1.0
mmol/L in gtt2. Thus it would seem possible that the previously observed
increase in obstetric interventions with increasing maternal age could be
related to an increasing, but still "normal", maternal glucose level.

There are a large number of different reasons as to why a decision could be

made to recommend either an elective or an emergency Caesarean section,
in addition to conventional obstetric indications there are also social and
demographic indications like the socio-economic status of the mother (Gould
et al, 1989), obstetrician preferences (Goyer et al, 1989) and increasing
maternal age (Peipert et al, 1993). Vaginal delivery compared to a Caesarean
section, even after a previous Caesarean section (Miller et al, 1994), has a
lower complication and death rate (Petti et al. 1982, Miller et al, 1988) avoids
the psychological impact of a surgical delivery (Eriksen et al, 1989) and is less
expensive particularly with a decreased length of hospital stay (Clark et al,
1991).

As dietary intervention in women with GDM can reduce the number of large
babies and hence one of the major indications for a Caesarean section, it is
tempting to postulate that dietary intervention in women without GDM but with
a high normal glucose level may also reduce the Caesarean section rate.

These results demonstrate in normal women that, after correcting for other
variables, there is an increasing probability of an assisted delivery, principally
an emergency Caesarean section, as the gtt2 level increases. This was a
particular problem for women with a gtt2 result of 7.0 - 7.9 mmol/L.
Pregnancy induced hypertension (PIH) is a poorly understood and probably
heterogeneous group of disorders which affects 6.2% of all pregnancies in
NSW (NSW Midwives Data Collection 1993). Hypertension of all kinds
(Jacobson et al, 1989) and specifically PIH is found with increased frequency
in women with GDM (Norlander et al, 1989; Langer et al, 1989; Drexel et al,
1988). An increased rate of PIH is also found in women without GDM who
have one abnormal value on their GTT (Lindsay et al, 1989). A Finnish

prospective study of the relationship between gestational glucose intolerance
and PIH is relevant to the present study (Suhonen et al, 1993). In this study
GDM was defined using lower glucose criteria than the ADIPS criteria and
therefore included many women who would have been in the non-GDM 7.07.9 mmol/L group herein reported. PIH was present in 19.8% of women with
GDM which was significantly higher than the rate of around 7.0% found in
controls.

The percentage of women with PIH in the current study increased from 7.2%
in those women with a gtt2 level ^ 3.9 mmol/L to 13.4% in those women with a
gtt2 level of 7.0 - 7.9 mmol/L. Those women with PIH had a significantly higher
gtt2 level than those women without this complication. The treated women
with GDM had a rate which was similar to the women with a gtt2 level of 7.0 7.9 mmol/L and certainly did not show the increasing trend which could have
been anticipated.

For normal women the increasing trend of PIH with rising levels of gtt2 was not
significant when the effect of the rising BMI was considered. The odds in
favour of PIH increased by 11.9% for each one unit increase in BMI. A very
substantial reduction in the odds was found for both gestational age and
parity. The reduction in odds for these factors could have been anticipated as
a women with PIH would be likely to have been induced early and, in addition,
may not be encouraged or inclined to have further pregnancies.

Thus while the risk of PIH increased as the gtt2 level increased the most likely
explanation for this was the increasing BMI rather than the glucose level per
se. However either an increasing gtt2 level or an increasing BMI could be
predictive of an increased risk of PIH.

A decision to induce labour can be made on a large number of factors.
Surprisingly, although the Chi-squared analysis of the contingency tables did
suggest a significant association with the rate of induction and the gtt2 level,
this did not increase as the gtt2 level increased. Rather the association was
caused by a lower than expected frequency in the women with a gtt2 level
between 5.0-5.9 mmol/L who were younger than the other groups. The overall
rate of induction for women in the lowest glucose group were similar the
overall rate for women in the highest glucose group.

Thompson et al (1994) reported that women with GDM had an overall
induction rate of 32%. Women with treated GDM in this series had the highest
overall rate of induction, a rate that was nearly twice that of the rate in nonGDM women in the 5.0 - 5.9 mmol/L gtt2 group. Again, like the increased rate
of assisted deliveries, this high rate is probably both traditional and
precautionary and is likely to gradually change with time.

The odds in favour of an induced birth increased by 6.2% for each one unit
increase in BMI and decreased by 12.7% for every 1.0 mmol/L increase in the
gtt2 level.

Large for gestational age (LGA) babies have in the past been a common
feature of women with GDM. Possible obstetric complications include birth
trauma, shoulder dystocia, asphyxia, meconium aspiration and neonatal
hypoglycaemia. A full term infant weighing more than 4500 g has a risk of
mortality three to four times that of infants with an average birth weight
(Spellacy et al, 1985). An increased rate of testing for GDM and an aggressive
modern approach to management have reduced the rate of this complication

to a level similar to that of the overall obstetric population (Norlander et al,
1989; Suhonen et al, 1993; Moses, 1994b). Macrosomia as a complication of
GDM is now most commonly found in women who have not been tested for
this problem or who are unreliable with the treatment advice (Moses, 1994b).
The rate of macrosomia is still frequently used as the single most important
indicator of the successful medical management of a woman with GDM
though it is increasingly recognised that the birthweight is more likely to be
determined by maternal variables than glycaemic control (Shelley-Jones et al,
1992; Cundy et al, 1993). The concern about macrosomia, while of arguable
value for the obstetric management, is assuming greater importance as the
effects of varying degrees of nutrition on the intrauterine development of fetal
organs is becoming increasingly recognised and acknowledged as an
associate and possible cause of many problems in adult life. Maternal
hyperglycaemia of any cause results in fetal hyperinsulinism and
overdevelopment of the fetal pancreatic islets.

Macrosomia can be defined in various ways including an arbitrary absolute
figure such as a birthweight of ^ 4000 g or relatively by using the tenth centile
of birthweight adjusted for gender and gestational age. The rate of
macrosomia in Canada has remained unchanged over the sixties and the
seventies (Boyd et al, 1983) while in Australia between the seventies and
eighties there has been a gradual increase corresponding to an increase in
the frequency of GDM (Shelley-Jones et al, 1992). While macrosomia is a
relatively common complication of diabetes and pregnancy it is still most
likely to be related to obvious factors like the gestational age of delivery, the
size of both parents, maternal age, parity, fetal gender and less obvious
factors like socioeconomic status (Ratten et al, 1974) and even geographical
features like altitude (Sack 1969).

In the series herein reported the rate of absolute macrosomia increased from
6.0% in normal women with a gtt2 result ^ 3.9 mmoi/L to 15.5% in the normal
women with a gtt2 result of 7.0 - 7.9 mmol/L. Overall those normal women who
had a macrosomic infant had a gtt2 result which was significantly higher than
those who did not. However when other variables were examined the
maternal gtt2 level no longer remained as a significant factor. There was an
anticipated increase in the rate of macrosomia with increasing gestational age
and also with increasing maternal preconception BMI. With respect to
absolute macrosomia the increased rate in women with increasing levels of
gtt2 could be explained by an increasing level of BMI.

In the series herein reported the rate of relative macrosomia increased from
6.7% in normal women with a gtt2 result ^ 3.9 mmol/L to 13.7% in normal
women with a gtt2 result of 7.0 - 7.9 mmol/L. Overall those women who had a
macrosomic infant had a gtt2 level which was significantly higher than those
who did not. However when other variables were examined the maternal gtt2
level no longer remained as a significant factor. There was an increase in the
rate of macrosomia with increasing maternal age and also with increasing
BMI. With respect to relative macrosomia the increased rate in women with
increasing levels of gtt2 could be explained mainly by an increasing level of
BMI.

Small for gestational age (SGA) infants also are an undesirable outcome of
any pregnancy and recent epidemiological data suggests a link between
reduced fetal growth and the adult development of hypertension (Barker et al,
1990) and NIDDM (Barker et al. 1993b). Reduced fetal growth can be due to
a variety of causes (King et al, 1994) and even possible over treatment of
GDM (Langer et al, 1989). Langer et al (1989) felt that the fetus would grow

within limits set by the nutrient supply and fetal insulin levels are susceptible
to substrate availability in either direction. The rate of SGA was significantly
related in treated women with GDM to the low mean daily maternal glucose
levels. In contrast, Dornhorst et al (1991) in a small series found no treated
woman with GDM had an infant with a birth weight less than the 10 th centile
and in the series herein reported there was no significant difference in the rate
of SGA for treated women with GDM compared to normal women when both
relative and absolute birth weights were considered.

In the series herein reported the rate of SGA in absolute terms was dependent
on the gestational age of delivery and not to the maternal gtt2 level or the
BMI. The rate of SGA in relative terms was not related to the maternal gtt2
level but decreased as the BMI increased. There is thus nothing to suggest in
normal women that maternal glucose levels per se will influence the rate of
SGA.

There have been a limited number of reports linking maternal glucose levels
with the rate of macrosomia. Leiken et al (1987) felt that minor degrees of
glucose intolerance were likely to result in an increased rate of macrosomia.
However the maternal glucose level was not specified and testing had been
done only on women with historical risk factors for GDM. In addition, although
different variables were considered as the possible cause of this association,
the maternal BMI was not examined. The following year Witter et al (1988)
also concluded that minor degrees of carbohydrate intolerance were
associated with an increased risk of macrosomia though they felt that the 50 g
glucose 1-hour screening test was a poor discriminator.

In 1994 Khan et al published a report on a large number of Pakistani women

relating maternal glucose results to the rate of macrosomia. This study has
many similarities and also some notable differences to the present series. All
pregnant women attending the Aga Khan University Medical Center in
Karachi had a 75 g non-fasting glucose challenge test (GCT) at 16-20 weeks
gestation with a single venous glucose sample taken at 2 hours. If the result
was > 7.8 mmol/L a GTT was carried out. Those women with a normal GCT
and those women with an abnormal GCT and a normal GTT were stratified
into different groups depending upon their 2 hour glucose response to the
GCT.

The rate of macrosomia, defined as a birthweight > 4000 g, increased from
1.2% in women with a glucose < 4.5 mmol/L to 9.5% in women with a glucose
> 7.8 mmol/L. Similar significant trends were found when the 90 th and 95 th
birthweight centiles were used. Macrosomia was not related to the gestational
age of delivery, probably because pre and post term deliveries had been
excluded.

There are both close similarities and some differences between the study of
Khan et al and the present study. The population studied were Pakistani
women who undoubtedly would have had a lower birthweight than the
predominantly Anglo-Saxon population group herein reported. Testing was
done at an earlier stage of pregnancy which would have reduced the number
of abnormal results to the GCT and thus would have led some women to be
included in the non-GDM group who would probably have been classified
differently if the test had been done 8-10 weeks later. The GCT was also
done in a non-fasting state though there is now evidence to suggest that this is
unlikely to make any major difference to the result (Gough et al. 1970). The
use of a 75 g glucose load and the 2 hour glucose sample were the same as

the present study. The use of a glucose result ^ 7.9 mmol/L to define
abnormality Is similar to the value of ^ 8.0 mmol/L recommended by ADIPS
and used In this study. No adjustment was made for the fetal gender In
determining the birthwelght centlles. Whereas Khan et al have found an
Increase in the rate of macrosomla with increasing maternal glucose levels,
no adjustment was made for maternal BMI. In the present study the maternal
BMI rather than the gtt2 level was the Important factor.

Jarrett (1993) in a deliberately provocative review argued that GDM was a
non-diagnosis and that any association between fetal birthwelght and
maternal glucose is lost when adjustments are made for maternal weight and
age. Leiken et al (1987) and Boyd et al (1983) found that lean women have a
lower rate of macrosomla. Green et al (1991) found that maternal body habitus
was the strongest predictor of fetal birthwelght. In the study by Green et al
there was no significant relationship between the maternal glucose level on a
screening test and fetal birthwelght after adjustment for the gestational age of
delivery, fetal gender, parity, ethnicity and BMI. However after adjustment for
the above variables there was a progressive increase In fetal birthwelght for
increasing levels of BMI. There are two possible difficulties with these
observations. BMI was determined at the time of the screening test at the
beginning of the third trimester and both overweight women and women with
GDM gain relatively less weight during pregnancy (Snyder et al, 1994; Cundy
et al, 1993). Cundy et al found that the fetal birthwelght In women with
established diabetes and GDM was correlated with the preconception BMI
and not with glycaemic control or with the glucose level in control (non
diabetic) pregnancies. Women who were diagnosed as having GDM appear
to have been included in the overall figures with no mention of any treatment.

Not withstanding these confounding variables, the present study also agrees
with the above reports that fetal birthweight and the rate of macrosomia are
related to maternal glucose levels only because maternal glucose levels in
normal women are largely determined by the maternal BMI. The odds in
favour of a baby weighing ^ 4000 g increased by 7.5% for each one unit
increase in BMI and the odds in favour of a baby being above the 90 th centile
for gestational age and gender increase by 9.6% for each one unit increase in
BMI.

Morbidity for the purposes of this survey was defined according to the
question on the Midwives form - "Did the baby require admission to a separate
facility/nursery for special care or observation". Morbidity, in this series, is thus
dependent upon the availability of a designated special care area. Within the
lllawarra area a special care nursery (SCN) was only available at the
Wollongong hospital and deliveries at Shellharbour hospital were therefore
not included in the analysis. The decision to admit a baby to the SCN was
made by the obstetrician/ paediatrician responsible for the delivery and was
made independently of any possible knowledge the normal maternal glucose
level.

The normal women who had their baby admitted to the SCN had a higher
mean gtt2 than the normal women who did not and the odds in favour of an
admission increased by 22.6% for each 1.0 mmol/L increase in the gtt2 result.
With respect to some obstetric and fetal outcomes the positive association with
the gtt2 level was largely explained by a higher maternal BMI. This does not
appear to be the case with respect to morbidity as the odds in favour of being
rated "Yes" for morbidity only increased by 3.5% for each one unit increase in
BMI.

It was not possible in this survey to determine the reason for admission to the
SCN as this was, in a majority of instances, not recorded in the medical
record. Decisions were no doubt precautionary as well as based upon
established medical indications. It is conventional practice to admit the babies
of all women who have had an assisted delivery to the SCN and about half of
the admissions were for this reason. However, after exclusion of those women
who had an assisted delivery the mean gtt2 level of those women whose
babies were admitted to SCN was still significantly higher than the gtt2 level of
those women whose babies were not admitted to the SCN. These results
indicate that whatever fetal indications were present leading to a decision to
admit to the SCN, these were more often found in women with a higher gtt2
level.

CONCLUSIONS

GDM is a potentially serious disorder requiring vigilance and effective medical
managennent. While most modern series of obstetric care have found no
significant differences in perinatal mortality between treated women with GDM
and the general obstetric population, this is partly due to a continuing
improvement in obstetric care and partly because it is most unlikely that there
are any diagnosed women with GDM who do not receive some form of
treatment. Historical lessons can only be ignored with peril. Perinatal mortality
is a finite end point but a very crude index of maternal and fetal care for
developed countries in the nineties. In a sophisticated medical environment,
and one that is becoming increasingly litigious, maternal and fetal outcomes
will be judged on more subtle criteria. The induction rate, the frequency of
assisted deliveries and the use of special care nurseries are all relevant to
"best practice" obstetrics and to administrators concerned with the costs of
health care. The intrauterine effects on the fetus of disorders or deviations of
maternal nutrition are likely to have profound effects on the later development
of adult diseases.

There can be no doubt that there are adverse fetal risks associated with
maternal glucose levels sufficiently high for a diagnosis of GDM to be
established. It is logical to presume that there will exist a continuum of risk for
maternal glucose levels of a lesser degree. The relationship of these risks to
the maternal glucose levels are more likely to be exponential rather than
linear. The statistical threshold for maternal glucose levels at which these risks
will become apparent will certainly vary depending on the risk being defined
and with the population examined. Where the risk will be defined will depend
upon the resources available for both detection and treatment.

An appropriate definition of GDIVI should be based on maternal and fetal
outcomes, both during the pregnancy and in later years. The risks to the fetus
seem to be present at a lower maternal glucose level than the glucose level
that will predict the future conversion of the mother to NIDDM. For the normal
women in this study the frequency of assisted deliveries and the probability of
being admitted to a special care nursery were all increased, after adjustment
for other variables, as the maternal glucose level increased. The rate of
macrosomia was also related to rising maternal glucose levels but could be
explained by a rising BMI. However in the clinical context, defining a
pregnancy at risk of having a macrosomic fetus on the basis of maternal
glucose levels and using maternal glucose levels to monitor the effects of
interventions are more likely to produce favourable outcomes than any
consideration of the BMI.

The gtt2 level in normal women is predictive of certain adverse pregnancy
outcomes. Dietary treatment in women with GDM can reduce the rate of
adverse outcomes associated with this condition. It is possible that dietary
interventions in normal women who have a gtt2 level in the higher range may
lead to an increased proportion of women with a normal pregnancy and a
reduction in health care costs.
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APPENDIX
Birthweiqht of males bv gestational aae.
Weeks gestation

mean (SD)

lOthcentile 90th centile

37.
38.
39.
40.
41.
42.

3094
3308
3471
3627
3709
3677

2465
2790
2954
3050
3180
3153

n = 32
n = 89
n = 119
n = 307
n = 120
n = 18

(459)
(445)
(381)
(472)
(432)
(406)

3805
3796
3906
4188
4240
4115

Birthweiqht of females bv gestational aae.
Weeks gestation

mean (SD)

lOthcentile 90th centile

37. n = 20
38. n = 90
39. n = 122
40. n = 303
41.n = 106
42. n = 25

2892
3068
3305
3461
3620
3517

2245
2615
2740
2876
3142
2910

(537)
(405)
(443)
(460)
(381)
(402)

3640
3600
3922
4022
4109
3950

Birthweiqht (total) bv gestational age.
Weeks gestation

mean (SD)

lOthcentile 90th centile

37.
38.
39.
40.
41.
42.

3016 (495)
3187 (441)
3387 (421)
3545 (473)
3667 (411)
3584(407)

2322
2700
2806
2930
3161
3018

n = 52
n = 179
n = 241
n = 610
n = 226
n = 43

3805
3686
3910
4130
4206
4084

